Antiva Biosciences, Inc.

📍 South San Francisco, United States👥 22 employees💰 Last funded Jun 2017
Biotechnology Research🌐 antivabio.com
Website LinkedIn
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Antiva Biosciences, Inc.?
Antiva Biosciences, Inc. has 1 investors on record on gritt.io.
When did Antiva Biosciences, Inc. last raise funding?
The most recent investment in Antiva Biosciences, Inc. recorded on gritt.io was in June 2017.
What industry is Antiva Biosciences, Inc. in?
Antiva Biosciences, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Antiva Biosciences, Inc. based?
Antiva Biosciences, Inc. is headquartered in South San Francisco, United States.